Occam Research Ltd is a boutique consultancy specialising in delivering academic quality research to support value demonstration for the pharmaceutical and device industries.
Insights & updates
Greening HTA? Do we need to rethink our approach to value?
At the recent ISPOR meeting in Montreal, Professor Andrew Briggs proposed things that may help or hinder the move to greener HTA methods. The presentation concluded with a warning that attempts to green HTA may in fact “exacerbate the very issues we aim to resolve” and to avoid this we must approach this move with humility and not haste.
Pricing combination products: not how but who?
As combination therapies - especially in oncology - become more commonplace, payers and HTA bodies are struggling to price them fairly. Despite technical progress in methods to attribute value between component treatments, the key question remains: who should implement these solutions?
CEA for Daridorexant in chronic Insomnia disorder
Health technology assessment (HTA) is built on a foundation of tried-and-tested conventions: lifetime horizons, a 'reference case' untainted by productivity, and a good old-fashioned faith in 'intention to treat' (ITT) analysis corrected by placebo control. But occasionally, a study comes along that quietly taps HTA on the shoulder and says, “What if we did things a bit differently?” We’ve just published a piece that does exactly that.
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.